RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000041.xml
Neuropediatrics 2019; 50(S 02): S1-S55
DOI: 10.1055/s-0039-1698170
DOI: 10.1055/s-0039-1698170
Oral Presentations
Neuromuscular Diseases and Varia
Onasemnogene Abeparvovec Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 1 (SMA1): Pivotal Phase 3 Study (STR1VE) Update
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
11. September 2019 (online)
Research Question: SMA1 is a rapidly progressing neurologic disease caused by biallelic survival motor neuron 1 gene (SMN1) deletion/mutation. The one-time SMN GRT onasemnogene abeparvovec (AVXS-101) addresses the genetic root cause of SMA. In a phase 1/2a study (NCT02122952), AVXS-101 resulted in exceptional event-free survival, motor function improvements, and motor milestone achievement in patients with SMA1. We report data from the multicenter, open-label, pivotal phase 3 STR1VE study (NCT03306277) investigating intravenous AVXS-101 in SMA1 patients (bi-allelic SMN1 mutations/deletions, 2xSMN2) aged
#
Die Autoren geben an, dass kein Interessenkonflikt besteht.